Design for 2nd part of Rett gene therapy TSHA-102 trial set
The U.S. Food and Drug Administration (FDA) agreed to Taysha Gene Therapies’ proposed design for the second part of a clinical trial testing TSHA-102, the company’s gene therapy for Rett syndrome, that’s expected to start this year. The study design is based on results from Part A of the…